Forward’s windfall

One investor’s view of what Forward Pharma should do with $1.25B windfall

At least one investor in Forward Pharma A/S (NASDAQ:FWP) views the biotech’s deal with Biogen Inc. (NASDAQ:BIIB) as akin to an acquisition with an upfront payment and a contingent value right, and hopes management will return the majority of the $1.25 billion

Read the full 428 word article

User Sign In